Skip to main content

PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline of Products to Address Prevalence and Unmet Medical Needs of Autism Spectrum Disorder

  • The CDC estimates that the prevalence of ASD in the United States is 1 in 36 children, with no approved pharmacologic treatments targeting the cause and symptoms
  • PaxMedica is developing novel anti-purinergic therapies for the treatment of ASD and other serious conditions with intractable neurologic symptoms, and is on a promising path to address the unmet medical needs and bring hope to millions
  • Company CEO Howard Weisman recently shared insights into PaxMedica’s achievements and advancements in a Fireside Chat video, underscoring the company’s commitment to groundbreaking therapies and transformative solutions

The prevalence of autism spectrum disorder (“ASD”) in the United States has risen to approximately 1 in 36 children, according to the Centers for Disease Control and Prevention (“CDC”). There are currently no approved pharmacologic treatments that target the causes and symptoms of ASD – the only treatment available on the market addresses symptoms of the condition rather than targeting the pathophysiology itself (

ASD is characterized by extreme versions of the processes governing the ability to focus attention and filter out sensory input. These processes often bring a wide range of special abilities, including the ability to hyperfocus on specific tasks, but they make normal everyday interactions and activities more…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

San Francisco, CA
415.949.5050 Office

BioMedWire is powered by IBN

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.